A 38-year-old woman comes to the clinic for a routine follow-up visit. Four weeks ago, she… — USMLE Step 3

A 38-year-old woman comes to the clinic for a routine follow-up visit. Four weeks ago, she was diagnosed with active pulmonary tuberculosis and began standard intensive phase treatment with isoniazid, rifampin, pyrazinamide, ethambutol, and pyridoxine. Today, she reports feeling well and notes that her initial cough, fevers, and night sweats have completely resolved. She denies experiencing any nausea, vomiting, abdominal pain, fatigue, dark urine, or yellowing of her eyes. Vital signs are within normal limits. Physical examination reveals clear lungs bilaterally and a soft, non-tender abdomen with no hepatomegaly.

Laboratory results are as follows:

Laboratory Test	Result	Reference Range
Aspartate aminotransferase (AST)	145 U/L	8-40 U/L
Alanine aminotransferase (ALT)	160 U/L	7-45 U/L
Alkaline phosphatase	85 U/L	40-120 U/L
Total bilirubin	0.8 mg/dL	0.1-1.2 mg/dL

Which of the following is the most appropriate next step in the management of this patient's therapy?

Continue the current medication regimen and repeat liver chemistries in 1 to 2 weeksAnswer
B
Discontinue isoniazid, rifampin, and pyrazinamide immediately
C
Discontinue pyrazinamide and substitute with moxifloxacin
D
Order an ultrasound of the right upper quadrant
E
Admit the patient to the hospital for observation and intravenous fluid hydration

Answer

Continue the current medication regimen and repeat liver chemistries in 1 to 2 weeks

The correct action is to continue the current medication regimen and repeat liver chemistries in 1 to 2 weeks. Isoniazid, rifampin, and pyrazinamide are hepatotoxic medications used during the intensive phase of tuberculosis treatment. It is very common for patients to develop mild to moderate asymptomatic elevations in serum transaminases (drug-induced transaminitis) due to hepatic adaptation, which does not require treatment cessation. Current guidelines mandate the immediate discontinuation of hepatotoxic antitubercular medications only if serum transaminases exceed

3

times the upper limit of normal (ULN) in the presence of hepatitis symptoms (e.g., nausea, vomiting, right upper quadrant pain, jaundice, fatigue), or if they exceed

5

times the ULN in a completely asymptomatic patient. This patient is feeling well and exhibits no symptoms, while her AST and ALT are elevated to roughly

3.5

4

times the ULN. Because she has not reached the

5

times ULN threshold for asymptomatic patients, the most appropriate management is to safely maintain her current, effective regimen while monitoring her liver chemistries closely (e.g., in 1 to 2 weeks) to ensure they do not continue to climb.

Step-by-Step Solution

Evaluate the patient's clinical presentation and isolated laboratory abnormalities.

The patient is completely asymptomatic, but her AST and ALT levels are elevated to roughly

3.5

4

times the upper limit of normal (ULN), with normal alkaline phosphatase and total bilirubin.

Establishing the presence or absence of hepatitis symptoms is the critical branch point in monitoring drug-induced hepatotoxicity.

Apply standard treatment and monitoring guidelines for antitubercular therapy.

Guidelines state that hepatotoxic drugs should only be stopped if transaminases are

>5

times the ULN in asymptomatic patients, or

>3

times the ULN in symptomatic patients (e.g., those with jaundice, nausea, or abdominal pain).

Differentiating between expected, benign hepatic adaptation and severe, dangerous hepatotoxicity prevents unnecessary disruption of life-saving therapy.

Determine the optimal intervention based on the clinical parameters.

Since the patient's transaminases are

<5

times the ULN and she lacks symptoms, her regimen should be continued without interruption, coupled with close serial monitoring.

Continuing the medications prevents the emergence of drug-resistant tuberculosis while keeping the patient under appropriate surveillance.

Key Concept

During tuberculosis therapy, mild asymptomatic elevations in transaminases represent hepatic adaptation; therapy should only be discontinued if transaminases exceed

5

times the upper limit of normal in asymptomatic patients or

3

times the limit in symptomatic patients.

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic